




National Cancer Institute and Frederick National Laboratory Annual Technology Showcase

Vladimir Popov, Ph.D.
Chief Innovation Officer
Center for Innovation and Strategic Partnerships (CISP)
FNLCR

Michael Salgaller, Ph.D.
Supervisor, Technology Analysis
and Marketing Unit
NCI Technology Transfer Center



It All Started with a November 2016 Meeting with Frederick County/City ...



Tech Showcase is a Unique Event

- ➤ Only NIH conference with potential licensees and collaborators as primary audience; agenda addresses their interests:
 - Technology pitches with a business case
 - Keynote address, voice of patient, success stories, industry-focused panels, networking
- ➤ Co-sponsorship agreement w/economic development offices of Frederick City/County and TEDCO to leverage resources, relationships and expertise
- ➤ PI opportunity: develop business-case presentations; mentored by Tech Analysis & Marketing Unit (TAMU) and FNL Partnership Development Organization (PDO)
- Post-doc opportunity: Technology Transfer Ambassadors Program (TTAP) presents quick invention pitches and posters from "potential commercial product" perspective
 Post-doc opportunity: Technology Transfer Ambassadors Program (TTAP)
 Post-doc opportunity: Technology Transfer Ambassadors Program (TTAP)

Event Addresses NCI & FNL Mission





Benefit Public Health



Stimulate Economic Development



Obtain return on public investment



Attract new R&D resources


IP utilized for technology development / commercialization







A Great Fit within Maryland



Even Better Fit within Frederick County

Tech Showcase Partners

- TEDCO



Frederick Co. Econ Dev



City of Frederick



- Federal Lab Consortium





- 100+ Life Science Companies
- Strong Cell Therapy & GMP Manufacturing Cluster
- Large Concentration of Major
 Government Funded Research
- Frederick County is #1 in NIH Research and Development Contract Awards

Incubation to Acceleration - Business Innovation Centers

- Frederick Innovative Technology Center Inc. (FITCI)
- Valogic 75,000 SF lab space
- Ballenger Bio 9,000 SF of R&D lab spec suites
- I-270 Innovation Labs 10,668 SF of R&D lab spec suites







Tech Showcase Builds and Strengthens Stakeholder Relationships








Expanding Our Target Audience

- The Usual Suspects:
 - Current customers, website and PI referrals
- Newer players in the ecosystem:
 - Nat'l/Int'l companies all stages
 - Investors
 - Entrepreneurs
 - Technology scouts
 - Trade associations and economic development entities
 - Foundations
 - Service providers (law, etc.)




They are referral sources once we create awareness







Who Attends?



Expanded Outreach via Established Network of National and International Stakeholders





6 countries dialed in







Event Addresses Common Myths About the NIH





Only basic research

FACT: Translational/clinical

Only work with academia

FACT: Hundreds of industry licenses & partnerships

Only work with U.S. companies

FACT: We partner internationally

Only study therapeutics

FACT: Devices/Dx/Biomarkers/Wearables/Tools

FACT: Prevention, Control and Causes

Only develop internal ideas

FACT: Ideas can originate in company partners



Agenda and Features

- > Keynote Addresses:
 - ★ NCI Directors, Dr. Jim Cherry, Kite Pharma Exec, MD Commerce Secretary, etc.
- Panels
- PI presentations
- Programmatic presentations
- Networking
- Voice of the patient
- TTAP next generation career training
- ★ Diversity a priority











Showcases and Educates on National Lab's Unique Capabilities and Expertise

- How to work, partner and collaborate
- Unique programs and capabilities available for collaborations/support
 - Ras program
 - Nanotech Characterization Lab (NCL)
 - Center for Advanced Pre-Clinical Research (CAPR)
 - CryoEM
- Unique services available to external research community
 - Only at FNL
 - Partnerships via Technical Service Agreements







Educating FNL and NCI Scientists: How to Communicate with Industry and Market Their Innovations

- > 10-min limit for presentation 8-12 slides including business case
 - Executive summary
 - What is the problem?
 - What is your solution?
 - Background and technology overview
 - Addressable market and opportunity
 - Competitive analysis
 - Summary
 - Licensing/Partnering POC








"Business Case" Information is Included (Antibody-Drug Conjugate for Neuroblastoma)

"Neuroblastoma is a \$10B Market"









"Business Case" Information is Included (Antibody-Drug Conjugate for Neuroblastoma)

ADC Market Landscape

Market Opportunity

- 6 ADCs FDA-approved
- 70%-80% of ADC manufacturing is outsourced
- Few Contract Manufacturing Organizations (CMOs) have resources to develop ADCs
- Strong market for new players who can overcome manufacturing challenges

Competitive Advantages

- ADCs provide:
 - enhanced efficacy versus naked antibodies
 - non-immunogenicity
 - killing neighboring cancer cells
- CD276 ADCs therapeutic benefit simultaneously ablates tumor cells and tumor associated stroma
- Clinical trial targeting rare cancers will facilitate commercialization for other solid tumors





Connecting Technology to Licensing/Partnering Opportunity

IP Status and Contact Information

PATENT STATUS:

Anti-CD276 Antibodies (B7H3) (NIH Ref. No. E-250-2014)

- U.S. Patent Number 10,604,582, Granted March 31,2020 (Filed March 16, 2017)
- U.S. Patent Application Number 16/812,980, Filed March 9, 2020
- European Patent Application Number 15772128.3, Filed April 18, 2017

Antibody-Drug Conjugates Specific for CD276 and Uses Thereof (NIH Ref. No. E-145-2019)

• U.S. Provisional Patent Application Number 62/947,135, Filed December 12, 2019

For Technical Information – Inventor: Brad St. Croix, Ph.D., NCI stcroix@ncifcrf.gov 301-846-7456



This Technology is Available for Licensing/Collaboration – Contact:

Rose Freel, Ph.D., NCI rose.freel@nih.gov

301-624-1257





A Complex Event Executed with Minimal Staff and Cost

- Planning Team (5 staff) organizes a seamless online and in-person experience
- Lots of moving parts:
 - 45 speakers from multiple internal and external organizations
 - Event website, marketing and social media
 - Concurrent panels
 - Stakeholder exhibit tables / posters
- Executed without a budget; our only cost:
 - Time of TTC's TAMU and FNL PDO Staff (year-round planning effort)
 - FNL's AV and Event Staff
 - Use of FNL facility
 - Co-sponsors provide light refreshments





Example of What it Takes to Execute: Director's Notes


TIME	PRESENTER	ACTION	CONTROLLING SLIDES	NOTES
1:31 - 1:32		Transition to Panel Sessions Attendees stay in main auditorium for Panel 1 or proceed to breakout room for Panel 2	Jeff	Display slide 6
TIME	PRESENTER	ACTION	CONTROLLING SLIDES	NOTES
1:32 – 2:20 pm	Panel Session 1 Auditorium and Main WebEx: Panel 1: How to "Tap into Resources and Work with the Frederick National Lab"	Moderator: Vladimir Popov, proceed to podium Three panelists, Nissley, Mudunuri & Deleage, proceed to chairs @ table on stage	"F - Panel 1 - How to tap into Resources FNL" Jeff S. display slides Vladimir control slides Display Slide 13 with QR code at the end	Maggie to monitor online WebEx and select first question from online audience Someone from AV Staff will bring mike to person in room if questions Display Slide 13 with QR code at the end

These detailed, notes are prepared for all 5+ hours of the conference by TTC's TAMU





Success Case: Telesis Therapeutics, Inc.





Recent key milestone: signed Cooperative Research and Development Agreement signed with FNLCR





FNL Outreach Activities



30 externally facing events in 2022

20 events serving as keynote, panelist, exhibitor, and/or meeting organizer



Regional

- BioHealth Capital Region Virtual Forum
- Maryland Life Sciences Bio Innovation Conference
- FLC –Mid-Atlantic Regional Meeting
- White House Initiative on HBCUs (WHIHBCU) NIH
 Session Panel on Partnerships & Funding Opportunities
- Federal Historically Black Colleges and Universities Industry Day

Local

- FNL and NCI Technology Showcase
- Ft. Detrick Alliance Quarterly Networking Breakfast
- Frederick Community College and FNL MOU Signing Event
- Bowie State University Mini-Expo: A Research Event with Arundel School in Zimbabwe (co-organizer)
- Foundation for the National Institutes of Health (FNIH)
 Biomarkers Consortium Cancer Steering Committee Meeting
- FNIH Cancer Steering Committee Annual Scientific Symposium FNIH Cancer Prevention Workshop
- FNL Summer Training Info Session to Georgetown University
- Women in Science Speak

National

- AUTM Annual Meeting
- American Association for Cancer Research (AACR)
 Meeting
- University Industry Demonstration Partnership (UIDP) Mission in Motion HBCU Event
- BIO International Convention
- FLC National Meeting
- Accelerating Therapeutics for Opportunities in Medicine (ATOM) Webinar: Alternative Approach and Business Model to Accelerate Drug Discovery
- SeroNet Investigators Meeting





The Tech Showcase is Part of a Year-Round Outreach Campaign – FNLCR and NCI TTC Working Together

NIH) NATIONAL CANCER INSTITUTE





NIH Events Management







frederick.cancer.gov

The Frederick National Laboratory for Cancer Research is government owned and contractor operated on behalf of the National Cancer Institute.

